The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine

This educational activity is based from a live satellite symposium from the 38th European Cystic Fibrosis Conference held in Brussels, Belgium. The expert faculty for this CME activity will present a comprehensive review of the effects of CFTR modulation therapeutics on cystic fibrosis disease progression. The new era of precision medicine has arrived and many patients can now be managed on the basis of phenotypes where very good healthcare outcomes can be achieved. Cystic fibrosis patients on treatment show new progress on lung function, BMI, exercise ability, infectious complications, life expectancy, co-morbid conditions such as diabetes, liver failure, bone disease, and overall quality of life. This clinically relevant activity also includes panel discussions with case presentations to advance your skills in caring for cystic fibrosis patients.

TARGET AUDIENCE

Pulmonologists, pediatricians, infectious disease, and other healthcare clinicians responsible for the care of patients with cystic fibrosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  • Review the principles of precision medicine as it pertains to CFTR modulation therapeutics.
  • Recognize risk factors and predictors of disease progression in the patient with cystic fibrosis.
  • Evaluate the impact of CFTR modulation therapeutics on disease progression in the patient with cystic fibrosis.
  • Describe current approaches to effectively manage patients on CFTR modulation therapeutics.

FACULTY

J. Stuart Elborn, MD 
Professor of Respiratory Medicine 
Dean, Medicine, Dentistry and Biomedical Science 
Queen’s University of Belfast 
Belfast, Northern Ireland, United Kingdom

Jane Davies, MD 
Professor of Paediatric Respirology and Experimental Medicine 
Imperial College London 
Honorary Consultant in Paediatric Respiratory Medicine 
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom  

Scott Bell, MD 
Director, Adult Cystic Fibrosis Centre 
The Prince Charles Hospital 
Group Leader, Lung Bacteria Group 
QIMR Berghofer Medical Research Institute 
Queensland, Australia

Nico Derichs, MD 
Director, CFTR Biomarker Center and Translational CF Research Group
Senior CF Physician, Paediatric and Adult CF Center 
Paediatric Pulmonology and Immunology 
Charité Universitätsmedizin Berlin 
Berlin, Germany

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty                                  

Relationship Identified With:

J. Stuart Elborn, MD

Consultant/Advisor: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated

Grant/Research Support: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation

Speaker’s Bureau: Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated

Jane Davies, MD            

Consultant/Advisor: Forest Laboratories, Inc.; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Proteostasis Therapeutics; Pulmocide Ltd; Verona Pharma plc; Vertex Pharmaceuticals Incorporated

Grant/Research Support: Novartis Pharmaceuticals Corporation

Speaker's Bureau: Forest Laboratories, Inc.; Vertex Pharmaceuticals Incorporated

Scott Bell, MD

Consultant/Advisor: PTC Therapeutics; Vertex Pharmaceuticals Incorporated

Grant/Research Support: Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated

Speaker’s Bureau: Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated

Nico Derichs, MD

Consultant/Advisor: Bayer Pharma AG

Grant/Research Support: Bayer Pharma AG; Vertex Pharmaceuticals Incorporated

Speaker’s Bureau: Novartis Pharmaceuticals Corporation

Planners, Managers, ReviewersSandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Stephanie Breslan and Bernard Abrams, MD, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

Provider Information 

Co-provided by the Elsevier Office of Continuing Medical Education, Dannemiller and AcademicCME. 

 

Course Open Date: August 21, 2015 | Course Expiration Date: August 20, 2016

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses)

Dannemiller is a provider approved by the California Board of Registered Nursing (CBRN), Provider Number 4229. This activity has been approved for 2.0 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, DanneMiller, AcademicCME, and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Course opens: 
08/21/2015
Course expires: 
08/20/2016
Rating: 
0

Available Credit

Accreditation Period

Course opens: 
08/21/2015
Course expires: 
08/20/2016
Please login or register to take this course.